Riboxin (Tablets, Capsules, Solution) Instructions for Use

Instructions
Dosage forms

ATC Code

C01EB (Other drugs for the treatment of heart diseases)

Active Substance

Inosine (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Drug normalizing myocardial metabolism, reducing tissue hypoxia

Pharmacotherapeutic Group

Metabolic agent

Pharmacological Action

Inosine belongs to the group of drugs that regulate metabolic processes.

The drug is a precursor for the synthesis of purine nucleotides: adenosine triphosphate and guanosine triphosphate.

It has antihypoxic, metabolic, and antiarrhythmic effects. It increases the energy balance of the myocardium, improves coronary circulation, and prevents the consequences of intraoperative renal ischemia. It is directly involved in glucose metabolism and promotes the activation of metabolism under hypoxic conditions and in the absence of adenosine triphosphate.

It activates the metabolism of pyruvic acid to ensure the normal process of tissue respiration and also promotes the activation of xanthine dehydrogenase. It stimulates the synthesis of nucleotides and enhances the activity of some enzymes of the Krebs cycle. Penetrating into cells, it increases the energy level, has a positive effect on metabolic processes in the myocardium, increases the force of heart contractions, and promotes more complete relaxation of the myocardium in diastole, resulting in an increase in stroke volume.

It reduces platelet aggregation and activates tissue regeneration (especially of the myocardium and the mucous membrane of the gastrointestinal tract).

Pharmacokinetics

It is well absorbed in the gastrointestinal tract. It is metabolized in the liver with the formation of glucuronic acid and its subsequent oxidation. It is excreted by the kidneys in small amounts.

Indications

It is prescribed for adults in the complex therapy of coronary heart disease, after myocardial infarction, and for cardiac arrhythmias caused by the use of cardiac glycosides.

It is prescribed for hepatitis, cirrhosis, fatty liver dystrophy caused by alcohol or drugs, and urocorporphyria.

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
B15	Acute hepatitis A
B16	Acute hepatitis B
B17	Other acute viral hepatitis
B18	Chronic viral hepatitis
E80.1	Porphyria cutanea tarda
I20	Angina pectoris
I21	Acute myocardial infarction
I49.8	Other specified cardiac arrhythmias
K71	Toxic liver disease
K73	Chronic hepatitis, not elsewhere classified
K74	Fibrosis and cirrhosis of liver
K76.0	Fatty (change of) liver, not elsewhere classified

ICD-11 code	Indication
1E50.0	Acute hepatitis A
1E50.1	Acute hepatitis B
1E50.Z	Acute viral hepatitis, unspecified
1E51.Z	Chronic viral hepatitis, unspecified
4A85.00	Drug hypersensitivity-induced liver disease
5C58.10	Porphyria cutanea tarda
BA40.Z	Angina pectoris, unspecified
BA41.Z	Acute myocardial infarction, unspecified
BC62	Accessory pathway
BC65.0	Long QT syndrome
BC65.1	Brugada syndrome
BC65.2	Short QT syndrome
BC65.3	Early repolarization syndrome
BC65.4	Idiopathic ventricular fibrillation
BC65.Z	Cardiac arrhythmia associated with genetic anomalies, unspecified
BC71.Z	Ventricular tachyarrhythmia, unspecified
BC81.6	Inappropriate sinus tachycardia
BC81.Z	Supraventricular tachyarrhythmia, unspecified
BC8Z	Supraventricular arrhythmia, unspecified
BC90	Atrioventricular nodal rhythm
BE2Y	Other specified diseases of the circulatory system
DB92.0	Non-alcoholic fatty liver disease without steatohepatitis
DB92.Y	Other specified non-alcoholic fatty liver disease
DB92.Z	Non-alcoholic fatty liver disease, unspecified
DB93	Fibrosis or cirrhosis of liver
DB95.Z	Drug-induced or toxic liver disease, unspecified
DB97.2	Chronic hepatitis, not elsewhere classified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Capsules, Solution

It is used orally and intravenously (bolus or drip). The dose, regimen, and duration of use are set individually, depending on the indications and dosage form.

Tablets

It is prescribed for adults orally, before meals.

The daily dose for oral administration is 0.6-2.4 g. In the first days of treatment, the daily dose is 0.6-0.8 g (200 mg 3-4 times a day). In case of good tolerance, the dose is increased (on the 2nd-3rd day) to 1.2 g (0.4 g 3 times a day), if necessary – up to 2.4 g per day.

The duration of the course is from 4 weeks to 1.5-3 months.

For urocorporphyria, the daily dose is 0.8 g (200 mg 4 times a day). The drug is taken daily for 1-3 months.

Adverse Reactions

Allergic reactions in the form of urticaria, skin itching, and skin hyperemia are possible (drug withdrawal is required). Rarely, during treatment with the drug, the concentration of uric acid in the blood increases and gout exacerbates (with long-term use).

Contraindications

Hypersensitivity to the drug, gout, hyperuricemia. Fructose intolerance and glucose/galactose malabsorption syndrome or sucrase/isomaltase deficiency.

With caution renal failure, diabetes mellitus.

Use in Pregnancy and Lactation

The safety of using Riboxin during pregnancy and lactation has not been established. The use of Riboxin is contraindicated during pregnancy. Breastfeeding should be discontinued during treatment with Riboxin.

Use in Renal Impairment

With caution: renal failure.

Special Precautions

During treatment with Riboxin, the concentration of uric acid in the blood and urine should be monitored.

Information for patients with diabetes mellitus: 1 tablet of the drug corresponds to 0.00641 bread units.

It does not affect the ability to drive vehicles and operate machinery requiring increased concentration.

Drug Interactions

Immunosuppressants (azathioprine, antilympholin, cyclosporine, thymodepressin, etc.) when used simultaneously reduce the effectiveness of Riboxin.

Storage Conditions

In a dry, light-protected place at a temperature not exceeding 25°C (77°F). Keep out of reach of children.

Shelf Life

Shelf life. 3 years. Do not use after the expiration date printed on the package.

Dispensing Status

The drug is dispensed by prescription.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Riboxin [Mapichem AG (Switzerland)]
Solution for intravenous administration 100 mg/5 ml: amp. 10 pcs.

Marketing Authorization Holder

Mapichem AG (Switzerland)

Manufactured By

Shandong Weifang Pharmaceutical Factory, Co. Ltd. (China)

Dosage Form

Riboxin

Solution for intravenous administration 100 mg/5 ml: amp. 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration	1 ml	1 amp.
Inosine	20 mg	100 mg

5 ml – ampoules (10) – cardboard packs.

Riboxin [Mapichem AG (Switzerland)]
Solution for intravenous administration 200 mg/10 ml: amp. 10 pcs.

Marketing Authorization Holder

Mapichem AG (Switzerland)

Manufactured By

Shandong Weifang Pharmaceutical Factory, Co. Ltd. (China)

Dosage Form

Riboxin

Solution for intravenous administration 200 mg/10 ml: amp. 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration	1 ml	1 amp.
Inosine	20 mg	200 mg

10 ml – ampoules (10) – cardboard packs.

Riboxin [Mapichem AG (Switzerland)]
Film-coated tablets, 200 mg: 50 pcs.

Marketing Authorization Holder

Mapichem AG (Switzerland)

Manufactured By

Jinan Mingxin Pharmaceutical, Co. Ltd. (China)

Dosage Form

Riboxin

Film-coated tablets, 200 mg: 50 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets	1 tab.
Inosine	200 mg

50 pcs. – polymer bottles (1) – cardboard packs.

Riboxin [Atoll LLC (Russia)]
Solution for intravenous administration 20 mg/ml: 5 ml or 10 ml amp. 5 or 10 pcs.

Marketing Authorization Holder

Atoll LLC (Russia)

Manufactured By

Ozon, LLC (Russia)

Dosage Form

Riboxin

Solution for intravenous administration 20 mg/ml: 5 ml or 10 ml amp. 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration transparent, colorless or slightly colored.

	1 ml
Inosine	20 mg

Excipients : hexamethylenetetramine – 2 mg, sodium hydroxide solution 1 M – to pH 7.8-8.6, water for injection – up to 1 ml.

5 ml – ampoules (5) – contour cell packs (1) – cardboard packs.
5 ml – ampoules (5) – cardboard trays (1) – cardboard packs.
5 ml – ampoules (5) – contour cell packs (2) – cardboard packs.
5 ml – ampoules (5) – cardboard trays (2) – cardboard packs.
10 ml – ampoules (5) – contour cell packs (1) – cardboard packs.
10 ml – ampoules (5) – cardboard trays (1) – cardboard packs.
10 ml – ampoules (5) – contour cell packs (2) – cardboard packs.
10 ml – ampoules (5) – cardboard trays (2) – cardboard packs.

Riboxin [Binnopharm JSC (Russia)]
Film-coated tablets, 200 mg: 20, 30, or 50 pcs.

Marketing Authorization Holder

Binnopharm JSC (Russia)

Dosage Form

Riboxin

Film-coated tablets, 200 mg: 20, 30, or 50 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets	1 tab.
Inosine	200 mg

10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.

Riboxin [Biosintez, PJSC (Russia)]
Solution for intravenous administration 100 mg/5 ml: amp. 5 or 10 pcs.

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Riboxin

Solution for intravenous administration 100 mg/5 ml: amp. 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration	1 ml	1 amp.
Inosine	20 mg	100 mg

5 ml – ampoules (5) – cardboard packs.
5 ml – ampoules (10) – cardboard packs.
5 ml – ampoules (5) – plastic contour packs (2) – cardboard packs.

Riboxin [Biosintez, PJSC (Russia)]
Solution for intravenous administration 200 mg/10 ml: amp. 5 or 10 pcs.

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Riboxin

Solution for intravenous administration 200 mg/10 ml: amp. 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration	1 ml	1 amp.
Inosine	20 mg	200 mg

10 ml – ampoules (5) – cardboard packs.
10 ml – ampoules (10) – cardboard packs.
10 ml – ampoules (5) – plastic contour packs (2) – cardboard packs.

Riboxin [Biosintez, PJSC (Russia)]
Coated tablets, 200 mg: 50 pcs.

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Riboxin

Coated tablets, 200 mg: 50 pcs.

Dosage Form, Packaging, and Composition

Coated tablets	1 tab.
Inosine	200 mg

10 pcs. – contour cell packs (5) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.

Riboxin [Borisov Plant Of Medical Preparations, PJSC (Republic Of Belarus)]
Solution for intravenous administration 2% (100 mg/5 ml): amp. 10 pcs.

Marketing Authorization Holder

Borisov Plant Of Medical Preparations, PJSC (Republic Of Belarus)

Dosage Form

Riboxin

Solution for intravenous administration 2% (100 mg/5 ml): amp. 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration 2%	1 ml	1 amp.
Inosine	20 mg	100 mg

5 ml – ampoules (10) – cardboard packs.

Riboxin [Borisov Plant Of Medical Preparations, PJSC (Republic Of Belarus)]
Film-coated tablets 200 mg: 10, 20, 30, 40, or 50 pcs.

Marketing Authorization Holder

Borisov Plant Of Medical Preparations, PJSC (Republic Of Belarus)

Dosage Form

Riboxin

Film-coated tablets 200 mg: 10, 20, 30, 40, or 50 pcs.

Dosage Form, Packaging, and Composition

Coated tablets	1 tab.
Inosine	200 mg

Riboxin [Velpharm, LLC (Russia)]
Solution for intravenous administration 20 mg/1 ml: amp. 5 ml or 10 ml 5 or 10 pcs.

Marketing Authorization Holder

Velpharm, LLC (Russia)

Dosage Form

Riboxin

Solution for intravenous administration 20 mg/1 ml: amp. 5 ml or 10 ml 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration in the form of a transparent, colorless or weakly colored liquid.

	1 ml
Inosine	20 mg

Excipients: propylene glycol, sodium hydroxide, sodium sulfite anhydrous, diluted acetic acid 30%, water for injections.

5 ml – ampoules (5) – contour cell packs (1) – cardboard packs.
5 ml – ampoules (5) – contour cell packs (2) – cardboard packs.
10 ml – ampoules (5) – contour cell packs (1) – cardboard packs.
10 ml – ampoules (5) – contour cell packs (2) – cardboard packs.

Riboxin [Grotex, LLC (Russia)]
Solution for intravenous administration 20 mg/1 ml: amp. 5 ml or 10 ml 10 pcs.

Marketing Authorization Holder

Grotex, LLC (Russia)

Dosage Form

Riboxin

Solution for intravenous administration 20 mg/1 ml: amp. 5 ml or 10 ml 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration colorless or slightly colored, transparent or almost transparent.

	1 ml
Inosine	20 mg

Excipients: methenamine – 2 mg, 1M sodium hydroxide solution – to pH 7.8-8.6, water for injections – to 1 ml.

5 ml – polyethylene ampoules (10) – cardboard packs.
10 ml – polyethylene ampoules (10) – cardboard packs.

Riboxin [Dalkhimpharm, JSC (Russia)]
Solution for intravenous administration 100 mg/5 ml: amp. 10 pcs.

Marketing Authorization Holder

Dalkhimpharm, JSC (Russia)

Dosage Form

Riboxin

Solution for intravenous administration 100 mg/5 ml: amp. 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration transparent, colorless or weakly colored.

	1 ml
Inosine	20 mg

Excipients: methenamine – 2 mg, 1M sodium hydroxide solution – to pH 7.8-8.6, water for injections – to 1 ml.

5 ml – ampoules (5) – contour cell packs (2) – cardboard packs.
5 ml – ampoules (10) – cardboard boxes.

Riboxin [Dalkhimpharm, JSC (Russia)]
Solution for intravenous administration 200 mg/10 ml: amp. 10 pcs.

Marketing Authorization Holder

Dalkhimpharm, JSC (Russia)

Dosage Form

Riboxin

Solution for intravenous administration 200 mg/10 ml: amp. 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration transparent, colorless or weakly colored.

	1 ml
Inosine	20 mg

Excipients: methenamine – 2 mg, 1M sodium hydroxide solution – to pH 7.8-8.6, water for injections – to 1 ml.

10 ml – ampoules (5) – contour cell packs (2) – cardboard packs.
10 ml – ampoules (10) – cardboard boxes.

Riboxin [Dalkhimpharm, JSC (Russia)]
Coated tablets, 200 mg: 50 pcs.

Marketing Authorization Holder

Dalkhimpharm, JSC (Russia)

Dosage Form

Riboxin

Coated tablets, 200 mg: 50 pcs.

Dosage Form, Packaging, and Composition

Coated tablets	1 tab.
Inosine	200 mg

10 pcs. – contour cell packs (5) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
10 pcs. – contour cell packs (PVC/paper) (5) – cardboard packs.

Riboxin [Irbit Chemical Pharmaceutical Plant, JSC (Russia)]
Coated tablets, 200 mg: 50 pcs.

Marketing Authorization Holder

Irbit Chemical Pharmaceutical Plant, JSC (Russia)

Dosage Form

Riboxin

Coated tablets, 200 mg: 50 pcs.

Dosage Form, Packaging, and Composition

Coated tablets	1 tab.
Inosine	200 mg

50 pcs. – dark glass jars (1) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.

Riboxin [Maxpharm, JSC (Russia)]
Film-coated tablets 200 mg: 10, 20, 30, 40, or 50 pcs.

Marketing Authorization Holder

Maxpharm, JSC (Russia)

Dosage Form

Riboxin

Film-coated tablets 200 mg: 10, 20, 30, 40, or 50 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets	1 tab.
Inosine	200 mg

Riboxin [Minskintercaps Up (Republic Of Belarus)]
Capsules 200 mg: 50 pcs.

Marketing Authorization Holder

Minskintercaps Up (Republic Of Belarus)

Dosage Form

Riboxin

Capsules 200 mg: 50 pcs.

Dosage Form, Packaging, and Composition

Capsules	1 caps.
Inosine	200 mg

10 pcs. – contour cell packs (5) – cardboard packs.

Riboxin [N.A. Semashko Moscow Chemical Pharmaceutical Preparations, JSC (Russia)]
Solution for intravenous administration 200 mg/10 ml: amp. 5 or 10 pcs., vials 5, 10, 20, 40 or 50 pcs.

Marketing Authorization Holder

N.A. Semashko Moscow Chemical Pharmaceutical Preparations, JSC (Russia)

Dosage Form

Riboxin

Solution for intravenous administration 200 mg/10 ml: amp. 5 or 10 pcs., vials 5, 10, 20, 40 or 50 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration	1 ml	1 amp.
Inosine	20 mg	200 mg

10 ml – ampoules (10) – cardboard packs.
10 ml – ampoules (5) – cardboard packs.
10 ml – ampoules (5) – contour plastic packs (2) – cardboard packs.
10 ml – vials (5) – cardboard packs.
10 ml – vials (10) – cardboard packs.
10 ml – vials (20) – cardboard packs.
10 ml – vials (40) – cardboard packs.
10 ml – vials (50) – cardboard packs.

Riboxin [N.A. Semashko Moscow Chemical Pharmaceutical Preparations, JSC (Russia)]
Coated tablets, 200 mg: 50 pcs.

Marketing Authorization Holder

N.A. Semashko Moscow Chemical Pharmaceutical Preparations, JSC (Russia)

Dosage Form

Riboxin

Coated tablets, 200 mg: 50 pcs.

Dosage Form, Packaging, and Composition

Coated tablets	1 tab.
Inosine	200 mg

10 pcs. – contour cell packs (5) – cardboard packs.

Riboxin [Novosibkhimpharm, JSC (Russia)]
Film-coated tablets, 200 mg: 50 pcs.

Marketing Authorization Holder

Novosibkhimpharm, JSC (Russia)

Manufactured By

Valenta Pharm, JSC (Russia)

Dosage Form

Riboxin

Film-coated tablets, 200 mg: 50 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets round, biconvex; on the cross-section two layers are visible: a yellow shell and a white or almost white core.

	1 tab.
Inosine	200 mg

Excipients: lactose monohydrate – 27 mg, microcrystalline cellulose – 34 mg, copovidone – 6.3 mg, calcium stearate – 2.7 mg.

Shell composition Opadry II (series 85) – 8 mg (partially hydrolyzed polyvinyl alcohol – 40%, macrogol 3350 – 20.2%, titanium dioxide (E171) – 8.45%, talc – 14.8%, aluminum lacquer based on indigo carmine (E132) – 0.15%, aluminum lacquer based on sunset yellow FCF (E110) – 0.15%, aluminum lacquer based on quinoline yellow (E104) – 16.39%).

10 pcs. – contour cell packs (5) – cardboard packs.

Riboxin [Novosibkhimpharm, JSC (Russia)]
Solution for intravenous injection 100 mg/5 ml: amp. 5, 10, or 20 pcs.

Marketing Authorization Holder

Novosibkhimpharm, JSC (Russia)

Dosage Form

Riboxin

Solution for intravenous injection 100 mg/5 ml: amp. 5, 10, or 20 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration	1 ml	1 amp.
Inosine	20 mg	100 mg

5 ml – ampoules (10) – cardboard packs.
5 ml – ampoules (10) – contour plastic packs (1) – cardboard packs.
5 ml – ampoules (10) – contour plastic packs (2) – cardboard packs.
5 ml – ampoules (5) – contour plastic packs (2) – cardboard packs.
5 ml – ampoules (5) – contour plastic packs (1) – cardboard packs.

Riboxin [Novosibkhimpharm, JSC (Russia)]
Solution for intravenous administration 200 mg/10 ml: amp. 5, 10 or 20 pcs.

Marketing Authorization Holder

Novosibkhimpharm, JSC (Russia)

Dosage Form

Riboxin

Solution for intravenous administration 200 mg/10 ml: amp. 5, 10 or 20 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration	1 ml	1 amp.
Inosine	20 mg	200 mg

10 ml – ampoules (10) – cardboard packs.
10 ml – ampoules (5) – cardboard packs.
10 ml – ampoules (5) – contour plastic packs (2) – cardboard packs.
10 ml – ampoules (5) – contour plastic packs (1) – cardboard packs.
10 ml – ampoules (10) – contour plastic packs (2) – cardboard packs.
10 ml – ampoules (10) – contour plastic packs (1) – cardboard packs.

Riboxin [Ozon, LLC (Russia)]
Film-coated tablets, 200 mg: 10, 20, 25, 30, 40, 50, 75, 100, 125, or 250 pcs.

Marketing Authorization Holder

Ozon, LLC (Russia)

Manufactured By

Ozon, LLC (Russia)

Ozon Pharm, LLC (Russia)

Dosage Form

Riboxin

Film-coated tablets, 200 mg: 10, 20, 25, 30, 40, 50, 75, 100, 125, or 250 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets white or almost white, round, biconvex; on the cross-section visible: a white or almost white core; the presence of slight surface roughness is allowed.

	1 tab.
Inosine	200 mg

Excipients: microcrystalline cellulose (MCC-101) – 40 mg, sucrose – 40 mg, potato starch – 17 mg, povidone K25 – 10 mg, croscarmellose sodium – 6 mg, magnesium stearate – 3 mg, purified water – 4 mg.

Shell composition hypromellose – 5.5 mg, polysorbate-80 – 1.5 mg, titanium dioxide – 3 mg.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
25 pcs. – contour cell packs (1) – cardboard packs.
25 pcs. – contour cell packs (2) – cardboard packs.
25 pcs. – contour cell packs (3) – cardboard packs.
25 pcs. – contour cell packs (4) – cardboard packs.
25 pcs. – contour cell packs (5) – cardboard packs.
25 pcs. – contour cell packs (10) – cardboard packs.

Riboxin [Promomed Rus LLC (Russia)]
Solution for intravenous administration 100 mg/5 ml: amp. 5 or 10 pcs., vials 5, 10, 20, 40 or 50 pcs.

Marketing Authorization Holder

Promomed Rus LLC (Russia)

Dosage Form

Riboxin

Solution for intravenous administration 100 mg/5 ml: amp. 5 or 10 pcs., vials 5, 10, 20, 40 or 50 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration	1 ml	1 amp.
Inosine	20 mg	100 mg

5 ml – ampoules (10) – cardboard packs.
5 ml – ampoules (5) – contour plastic packs (2) – cardboard packs.
5 ml – ampoules (5) – contour plastic packs (1) – cardboard packs.
5 ml – vials (5) – cardboard packs.
5 ml – vials (10) – cardboard packs.
5 ml – vials (20) – cardboard packs.
5 ml – vials (40) – cardboard packs.
5 ml – vials (50) – cardboard packs.

Riboxin [Promomed Rus LLC (Russia)]
Film-coated tablets, 200 mg: 50 pcs.

Marketing Authorization Holder

Promomed Rus LLC (Russia)

Dosage Form

Riboxin

Film-coated tablets, 200 mg: 50 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets	1 tab.
Inosine	200 mg

10 pcs. – contour cell packs (5) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.

Riboxin [Slavic Pharmacy, LLC (Russia)]
Solution for intravenous administration 20 mg/ml: 5 ml or 10 ml amp. 5 pcs.

Marketing Authorization Holder

Slavic Pharmacy, LLC (Russia)

Manufactured By

Slavic Pharmacy, LLC (Russia)

Dosage Form

Riboxin

Solution for intravenous administration 20 mg/ml: 5 ml or 10 ml amp. 5 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration	1 ml
Inosine	20 mg

5 ml – ampoules (5) – carton packs.
10 ml – ampoules (5) – carton packs.

Riboxin [Tatkhimpharmpreparaty, JSC (Russia)]
Film-coated tablets, 200 mg: 50 pcs.

Marketing Authorization Holder

Tatkhimpharmpreparaty, JSC (Russia)

Dosage Form

Riboxin

Film-coated tablets, 200 mg: 50 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets from light yellow to yellow-orange in color, round, biconvex, slightly rough; the cross-section shows two layers: a core of white or white with a slight yellowish tint and a coating from light yellow to yellow-orange in color.

	1 tab.
Inosine	200 mg

Excipients: potato starch 54.1 mg, methylcellulose 3.2 mg, sucrose 10 mg, stearic acid 2.7 mg.

Coating composition Opadry II yellow (polyvinyl alcohol, titanium dioxide, talc, macrogol 3350 (polyethylene glycol 3350), iron (III) oxide, aluminum lake based on quinoline yellow) – 8 mg.

10 pcs. – contour cell blisters (5) – carton packs.
25 pcs. – contour cell blisters (2) – carton packs.

Riboxin [Ellara, LLC (Russia)]
Solution for intravenous administration 20 mg/ml: 5 ml amp. 5 or 10 pcs.

Marketing Authorization Holder

Ellara, LLC (Russia)

Manufactured By

Ellara, LLC (Russia)

Dosage Form

Riboxin

Solution for intravenous administration 20 mg/ml: 5 ml amp. 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration transparent, colorless or yellowish.

	1 ml
Inosine	20 mg

Excipients: hexamethylenetetramine – 2 mg, sodium hydroxide solution 1 M – to pH 7.8-8.6, water for injection – up to 1 ml.

5 ml – ampoules of neutral glass (5) – contour cell blisters (1) – carton packs.
5 ml – ampoules of neutral glass (5) – contour cell blisters (2) – carton packs.
5 ml – ampoules of neutral glass (5) – carton packs.
5 ml – ampoules of neutral glass (10) – carton packs.
5 ml – ampoules of neutral glass (5) – contour cell blisters (4) – carton packs (for hospitals).
5 ml – ampoules of neutral glass (5) – contour cell blisters (5) – carton packs (for hospitals).
5 ml – ampoules of neutral glass (5) – contour cell blisters (10) – carton packs (for hospitals).
5 ml – ampoules of neutral glass (5) – contour cell blisters (50) – carton packs (for hospitals).
5 ml – ampoules of neutral glass (5) – contour cell blisters (100) – carton packs (for hospitals).

Medixlife (Author)

View all posts Profile link